Keyphrases
Novel Therapeutics
100%
Type 2 Diabetic Patients
100%
Incretin Mimetics
100%
A1 Receptor
50%
Type 2 Diabetes Mellitus (T2DM)
50%
Glucagon-like
50%
Liraglutide
50%
Exenatide
50%
Quality of Life
25%
Cardiovascular Risk
25%
Clinical Data
25%
Beneficial Effects
25%
Glucose Concentration
25%
Receptor Subtypes
25%
PubMed
25%
Disease-associated
25%
Blood Pressure
25%
Receptor Agonist
25%
Pharmacology
25%
Safety Self-efficacy
25%
Tolerability
25%
MEDLINE
25%
Weight Loss
25%
Incretin System
25%
Insulin Secretion
25%
Vascular Risk Factors
25%
Tight Glycemic Control
25%
Lipid Profile
25%
Early Death
25%
Combination Regimen
25%
Metabolic Disease
25%
Pancreatic β-cells
25%
Hypoglycemia Risk
25%
Blood Changes
25%
Diabetes Management
25%
Low Glucose
25%
Antidiabetes Agent
25%
Insulinotropic Activity
25%
Insulin Synthesis
25%
Anti-diabetes
25%
Anti-diabetes Drugs
25%
Medicine and Dentistry
Patient with Type 2 Diabetes
100%
Incretin
100%
Maturity Onset Diabetes of the Young
40%
Liraglutide
40%
Exenatide
40%
Quality of Life
20%
Blood Pressure
20%
Diabetes
20%
Cardiovascular Risk
20%
Hypoglycemia
20%
Antidiabetic Agent
20%
Glucagon-Like Peptide-1 Agonist
20%
Insulin Release
20%
Beta Cell
20%
Glycemic Control
20%
Water-Electrolyte Imbalance
20%
Insulin Synthesis
20%
Glucagon Like Peptide 1 Receptor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Incretin
100%
Liraglutide
40%
Exendin 4
40%
Antidiabetic Agent
20%
Hypoglycemia
20%
Tolerability
20%
Cardiovascular Risk
20%
Glucagon Like Peptide 1 Receptor Agonist
20%
Metabolic Disorder
20%
Glucagon-Like Peptide 1 Receptor
20%